Coherent receives ISO 13485 certification for Goettingen facility

Article

Coherent Inc. has recently expanded its ISO 13485 certification in Europe to include the Excimer laser design and manufacturing facility located in Goettingen, Germany.

Santa Clara, Calif., Sept. 11, 2009 — Coherent Inc. (Santa Clara, CA) (Nasdaq: COHR) has recently expanded its ISO 13485 certification in Europe to include the Excimer laser design and manufacturing facility located in Goettingen, Germany. ISO 13485 is an international standard that defines the requirements of comprehensive quality management systems for the design, development, production, customer service and assembly of medical devices. ISO 13485 also specifies protocols for adherence to customer requirements and product improvement within the European regulatory framework for medical devices.

“Achieving ISO 13485 certification benefits all customers who integrate Coherent’s excimer laser products into their surgical systems for eye correction,” notes Heiner Felder, Quality Manager for Medical Products. “The Goettingen certification provides Coherent’s medical customer with expanded capabilities and supplements the existing ISO 13485 certification of the Munich facility. We have now successfully integrated and synchronized all our quality systems for excimer lasers within Coherent.”

Founded in 1966, Coherent, Inc. is a Russell 2000 Index company and a world leader in providing laser-based solutions to the commercial and scientific research markets. Please direct any questions to Heiner Felder, Quality Manager for Medical Products at +49 89 5892746 10. For more information about Coherent, including product and financial updates, visit our website at:
www.coherent.com/excimer

Contact details
Petra Wallenta, PR Manager Europe
+49 89 5892746 25
petra.wallenta@coherent.com

Heiner Felder
+49 89 5892746 10
heiner.felder@coherent.com

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.